VRG-145 / VRG Therap - LARVOL DELTA

Novamigra Therapeutics Secures ~€3 Million Funding to Advance First-in-Human Study of Migraine Prophylaxis Asset VRG-145 (Firstwordpharma Press Release) - "The proceeds will support the completion of CMC (Chemistry, Manufacturing, and Controls) development, as well as the execution of the company’s first-in-human pharmacokinetic (PK) and safety Phase 1 study....Based on regulatory guidance, Novamigra has finalized the design of its first-in-human Phase 1 study, a 36 healthy volunteer trial designed to assess the pharmacokinetics and safety of VRG-145."

Financing • New P1 trial • Migraine